Pharmaceuticals Global On demand · 24-48h

Global Pregnant Mare Serum Gonadotropin (PMSG) Market Strategic Research Report

Global Pregnant Mare Serum Gonadotropin (PMSG) Market Strate…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Pregnant Mare Serum Gonadotropin (PMSG) Market
$2882025
4.7%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: 1000 IU/Unit, 5000 IU/Unit, Others

By Application: Pig, Cattle, Sheep, Horse, Other Animals

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: MSD Animal Health, Ceva Santé Animale, Syntex SA, Bioveta, Ningbo Sansheng Biological Technology, Ningbo Second Hormone Factory, Chifeng Bo-en Pharmaceutical, Guangzhou Vbio-Pharma, JALLY, Ningbo Creator Animal Pharmaceutical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 96 pages
Market size 2025
$288
Million USD
Forecast CAGR
4.7%
2025-2032
Forecast 2032
$397.2
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Pregnant Mare Serum Gonadotropin (PMSG) market size is predicted to grow from US$ 288 million in 2025 to US$ 396 million in 2032; it is expected to grow at a CAGR of 4.7% from 2026 to 2032.

Pregnant Mare Serum Gonadotropin, or PMSG, is a complex glycoprotein that stimulates development of the ovarian follicle. It is an efficient substitute for Follicle Stimulating Gonadotropin (FSH) and Interstitial Cell Stimulating Hormone of the anterior pituitary gland. This hormone is also known as Equine Chorionic Gonadotropin.

Global key players of Pregnant Mare Serum Gonadotropin (PMSG) include MSD Animal Health, Ceva Santé Animale, Ningbo Sansheng Biological Technology, etc. The top three players hold a share about 60%. Europe is the largest market, and has a share about 40%, followed by China and North America with share 28% and 17%, separately. In terms of product specification, 5000 IU/Unit is the largest, occupied for a share of 41%. In terms of application, Pig is the largest field with a share about 62 percent.

This report presents a comprehensive overview of the global Pregnant Mare Serum Gonadotropin (PMSG) market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Specification

  • 1000 IU/Unit
  • 5000 IU/Unit
  • Others

Segment by Application

  • Pig
  • Cattle
  • Sheep
  • Horse
  • Other Animals

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Pregnant Mare Serum Gonadotropin (PMSG) market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Pig, Cattle, Sheep evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Pregnant Mare Serum Gonadotropin (PMSG) Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 4.7%
Regional growth momentum
Market share by segment
Key metrics
Base value
$288
2025
Forecast
$397.2
2032
CAGR
4.7%
2025–2032
Regiones
5
global
Key companies
MSD Animal HealthCeva Santé AnimaleSyntex SABiovetaNingbo Sansheng Biological TechnologyNingbo Second Hormone FactoryChifeng Bo-en PharmaceuticalGuangzhou Vbio-Pharma
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
1000 IU/Unit5000 IU/UnitOthers
By Application
PigCattleSheepHorseOther Animals

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 1000 IU/Unit
  • 3.1.3 5000 IU/Unit
  • 3.1.4 Others
  • 3.1.5 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Pig
  • 4.1.3 Cattle
  • 4.1.4 Sheep
  • 4.1.5 Horse
  • 4.1.6 Other Animals
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 MSD Animal Health
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Ceva Santé Animale
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Syntex SA
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Bioveta
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Ningbo Sansheng Biological Technology
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Ningbo Second Hormone Factory
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Chifeng Bo-en Pharmaceutical
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Guangzhou Vbio-Pharma
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 JALLY
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Ningbo Creator Animal Pharmaceutical
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Pregnant Mare Serum Gonadotropin (PMSG) market?
The global Pregnant Mare Serum Gonadotropin (PMSG) market is estimated at US$ 288 million in 2025 (base year) and is projected to reach US$ 396 million by 2032.
What is the forecast CAGR for the Pregnant Mare Serum Gonadotropin (PMSG) market?
The market is expected to grow at a CAGR of 4.7% from 2026 to 2032, expanding from US$ 288 million in 2025 to US$ 396 million in 2032, roughly 1.4 times its base-year value.
What is Pregnant Mare Serum Gonadotropin (PMSG)?
Pregnant Mare Serum Gonadotropin, or PMSG, is a complex glycoprotein that stimulates development of the ovarian follicle. It is an efficient substitute for Follicle Stimulating Gonadotropin (FSH) and Interstitial Cell Stimulating Hormone of the anterior pituitary gland. This hormone is also known as Equine Chorionic Gonadotropin.
What are the main segments of the Pregnant Mare Serum Gonadotropin (PMSG) market by specification?
By specification, the market is segmented into 1000 IU/Unit, 5000 IU/Unit and Others.
Which applications drive demand in the Pregnant Mare Serum Gonadotropin (PMSG) market?
Key applications covered include Pig, Cattle, Sheep, Horse and Other Animals.
Who are the key players in the Pregnant Mare Serum Gonadotropin (PMSG) market?
Key players profiled include MSD Animal Health, Ceva Santé Animale, Syntex SA, Bioveta, Ningbo Sansheng Biological Technology, Ningbo Second Hormone Factory, Chifeng Bo-en Pharmaceutical and Guangzhou Vbio-Pharma, among 10 companies covered in total.
Which regions and countries are covered for Pregnant Mare Serum Gonadotropin (PMSG)?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Pregnant Mare Serum Gonadotropin (PMSG) market report?
The report is intended for manufacturers and solution providers, distributors and end users in Pig, Cattle and Sheep, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Pregnant Mare Serum Gonadotropin (PMSG) market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.